Bicycle Therapeutics (BCYC) Research & Development (2018 - 2026)

Bicycle Therapeutics has reported Research & Development for 9 years, with the latest figure at $48.9 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 17.2% year-over-year to $48.9 million; the trailing twelve-month figure through Mar 2026 stood at $230.1 million (up 16.72% YoY), and the FY2025 full-year result was $240.3 million, up 38.92% from the prior year.
• Research & Development for Q1 2026 stood at $48.9 million, down from $51.8 million in the prior quarter.
• The five-year high for Research & Development was $71.0 million in Q2 2025, with the low at $14.3 million in Q1 2022.
• Historically, Research & Development has averaged $41.2 million across 5 years, with a median of $40.1 million in 2024.
• Annual changes were most pronounced in 2023 — Research & Development soared 125.5% — and 2026, when it declined 17.2%.
• Bicycle Therapeutics' Research & Development stood at $24.7 million in 2022, then soared by 80.82% to $44.7 million in 2023, then advanced by 11.37% to $49.8 million in 2024, then increased by 4.0% to $51.8 million in 2025, then decreased by 5.54% to $48.9 million in 2026.
• The last three Research & Development figures came in at $48.9 million (Q1 2026), $51.8 million (Q4 2025), and $58.4 million (Q3 2025), per Business Quant data.